Libero Thera
Libero Thera is a Japanese drug discovery R&D services company founded in 2018, operating with a small team and backed by UTokyo Innovation Platform and other Japan-focused investors to support pharmaceutical research and development.
- Company typePrivate
- Founded2018
- HeadquartersNihombashi-hamacho, Japan
- Headcount1–10
- GTM typeB2B
- OfferingServices
What Libero Thera does
Libero Thera is a privately held Japanese medical care company founded in 2018 that provides drug discovery research and development services. The company operates from Nihombashi-hamacho, Japan, with a small team of 1-10 employees, and is led by founder and president Iwao Nozawa and CEO Toru Sugaya.
The company has raised approximately $6.23M across two disclosed funding rounds: a $4.89M round in May 2021 and a $1.34M round in August 2024, both led by UTokyo Innovation Platform with participation from MP Healthcare Venture Management and other Japan-focused investors including Beyond Next Ventures, Miyagin Venture Capital, and Taiho Ventures. The investor syndicate — anchored by a University of Tokyo–affiliated vehicle and including a pharmaceutical strategic (Taiho Ventures) — is consistent with an early-stage Japanese biotech spinout leveraging academic research and pharma-aligned commercialization pathways.
Specific product details, technology platforms, pricing, customer relationships, and partnership economics are not disclosed in the available source material, and the company's website was inaccessible at the time of data collection. As a result, the precise nature of Libero Thera's drug discovery services — including therapeutic areas, modality, pipeline stage, and revenue model — cannot be characterized from the input data.
Libero Thera firmographics
Firmographics- Name
- Libero Thera
- Website
- https://liberothera.com
- Company type
- Private
- Founded year
- 2018
- Headcount range
- 1–10 employees
- Short description
- Libero Thera is a Japanese drug discovery R&D services company founded in 2018, operating with a small team and backed by UTokyo Innovation Platform and other Japan-focused investors to support pharmaceutical research and development.
- Ownership category
- akta.pro rank
Where Libero Thera is headquartered
LocationHeadquarters
- HQ city
- Nihombashi-hamacho
- HQ country
- Japan
- HQ region
- Asia
Markets served
Libero Thera business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations
Libero Thera product offering
Product offeringCore offering
Libero Thera is a medical care company that provides drug discovery research and development services. The company supports pharmaceutical innovation through its R&D activities, focusing on identifying and developing new therapeutic candidates for the medical and biopharmaceutical sectors.
Differentiator
Problem solved
Functional benefit
Products and services
- Drug Discovery Research and Development Services
Companies that use Libero Thera
Customer profileIdeal customer profiles1 record
Libero Thera technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Libero Thera partnerships and signals
Strategic signalRecent moves3 records
Expansion highlights3 records
Libero Thera competitors and assessment
Company assessmentDirect peers
- Charles River Laboratories: Global contract research organization providing integrated drug discovery and nonclinical development services including medicinal chemistry, in vivo pharmacology, and safety assessment. Directly comparable as a drug discovery R&D services provider serving pharma and biotech clients worldwide.
- WuXi AppTec: One of the world's largest CROs offering end-to-end drug discovery, preclinical, and clinical services. Direct peer for outsourced drug discovery R&D work globally and a major Asia-Pacific competitor for Japanese biotech clients.
- Evotec: Germany-based drug discovery CRO offering fully integrated services from target identification through preclinical development. Comparable business model focused on long-term discovery partnerships with pharma and biotech.
- Pharmaron: China-headquartered CRO providing drug discovery, preclinical, and clinical services across multiple therapeutic areas. Direct peer for Asian and global pharma outsourcing of discovery R&D work.
- Eurofins Discovery: Division of Eurofins Scientific offering drug discovery services including medicinal chemistry, in vitro pharmacology, ADME, and bioanalytical support. Directly comparable as a drug discovery R&D services provider.
- Inotiv: US-based contract research organization providing drug discovery and development services including preclinical research, safety assessment, and related scientific services. Comparable service offering to Libero Thera for outsourced discovery work.
- Curia: Contract development and manufacturing organization offering drug discovery, process chemistry, and development services from research through commercial manufacturing. Comparable as an integrated drug discovery services provider.
- Selvita: Poland-headquartered CRO providing drug discovery and development services including medicinal chemistry, in vitro and in vivo pharmacology, and integrated discovery programs. Comparable as a smaller-scale drug discovery CRO targeting biotech and pharma clients.
Broad incumbents
- Takeda Pharmaceutical: Japan's largest pharmaceutical company with significant in-house drug discovery operations across oncology, GI, neuroscience, and rare diseases. Comparable as the dominant Japanese pharma incumbent whose outsourcing decisions shape the addressable market for Libero Thera.
- Ono Pharmaceutical: Mid-to-large Japanese pharmaceutical company with drug discovery operations and a potential customer (and occasional competitor for talent) for Libero Thera's drug discovery services. Comparable as a Japanese pharma player in the broader discovery ecosystem.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights5 records
Customer concentration
Libero Thera financial estimates
Financial estimateRevenue estimate
Valuation estimate
Libero Thera leadership team
Management profileNumber of profiles
Profiles2 records
Libero Thera funding detail
Funding detailFunding overview
Funding rounds2 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Libero Thera M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Libero Thera
What does Libero Thera do?
Libero Thera is a medical care company that provides drug discovery research and development services. The company supports pharmaceutical innovation through its R&D activities, focusing on identifying and developing new therapeutic candidates for the medical and biopharmaceutical sectors.
When was Libero Thera founded?
Libero Thera was founded in 2018. It employs 1 to 10 people.
Where is Libero Thera based?
Libero Thera is headquartered in Nihombashi-hamacho, Japan, in the Asia region.
Who are Libero Thera's main competitors?
Direct peers on record are Charles River Laboratories, WuXi AppTec, Evotec, Pharmaron, Eurofins Discovery, Inotiv, Curia and Selvita. Broad incumbents are Takeda Pharmaceutical and Ono Pharmaceutical.
Does Libero Thera have an API?
No public API is recorded for Libero Thera.